Haematological Malignancies, Multiple Myeloma
Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
Beatrice M Razzo, Alfred L Garfall
touchREVIEWS in Oncology & Haematology. 2023;19(1):46–51 DOI: https://doi.org/10.17925/OHR.2023.19.1.46
Multiple myeloma (MM) is the second most common haematological malignancy, with upwards of 35,000 diagnoses in the USA each year.1,2 It remains a leading cause of blood cancer–related mortality worldwide, and although therapeutic advances have allowed for significant improvements in the median overall survival,3,4 the majority of patients still experience cycles of relapse that are eventually fatal.5 While patients with MM are living longer, a subgroup with high-risk disease at diagnosis still does poorly, with a median […]